Form 8-K - Current report:
SEC Accession No. 0001628280-25-004637
Filing Date
2025-02-10
Accepted
2025-02-10 16:03:29
Documents
15
Period of Report
2025-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20250210.htm   iXBRL 8-K 30159
2 EX-99.1 arwr-202502108kex991.htm EX-99.1 73639
6 ghvnqo5ppwcq000001a.jpg GRAPHIC 49974
  Complete submission text file 0001628280-25-004637.txt   311714

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20250210.xsd EX-101.SCH 1812
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20250210_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20250210_pre.xml EX-101.PRE 13066
17 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20250210_htm.xml XML 2829
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 25605698
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)